Artrya Limited (ASX:AYA): How Is Salix Commercial Adoption Developing in the US?

Aditi Sarkar

13 November 2026 03:25 PM AEDT

Artrya Limited (ASX:AYA): How Is Salix Commercial Adoption Developing in the US?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Artrya (ASX:AYA) traded at AUD 3.26 on 13 November 2026, down 5.23%.
Huntsville Hospital signed a five-year Salix commercial agreement.
September-quarter customer receipts were AUD 84,000.
The US rollout remains focused on customer adoption and scan usage.

Artrya Limited develops software for coronary artery disease assessment, with its Salix platform designed to support clinicians reviewing coronary computed tomography angiography images. Shares in Artrya (ASX:AYA) were trading at AUD 3.26 on 13 November 2026, down 5.23% during the session. The company's recent disclosures describe the expansion of commercial deployments in the United States, including a hospital agreement and efforts to increase use of its coronary plaque assessment capabilities.

Salix Platform and Clinical Workflow

Artrya (ASX:AYA) is commercialising an artificial intelligence-assisted, cloud-based platform intended to assist the interpretation and management of coronary artery disease. Its Salix offering includes coronary anatomy and plaque assessment modules. The Business model combines platform subscriptions with usage-based revenue, depending on customer arrangements. Its current commercial emphasis is the United States, where integration into clinical practice, physician adoption and reimbursement processes are important to recurring utilisation. Regulatory status must also be considered separately for different modules, rather than treating all products as having identical clearances.

US Customer Agreements and September Developments

During the September 2026 quarter, Huntsville Hospital Health System entered a five-year commercial agreement with Artrya. The hospital system became the first participant in the SAPPHIRE study to move to a full commercial arrangement. This matters operationally because the programme combines clinical evaluation with a route to contracted use, although the pace of further conversions is not assured. Artrya's quarter-end commentary also described higher Salix Coronary Plaque volumes at Tanner Health after a pre-authorisation workflow adjustment in mid-September. The company reported that elevated activity continued into October. Those developments describe customer engagement, but actual Revenue will depend on contracted terms and the number of scans processed.

Quarterly Cash Flow and Financial Context

For the three months ended 30 September 2026, Artrya reported AUD 84,000 of customer receipts, comprising subscriptions from its first two live commercial customers and per-scan receipts from Tanner Health. Net cash used in Operating Activities was approximately AUD 6.824 million. Staff payments totalled approximately AUD 3.594 million, with Research and Development payments of AUD 784,000 and product Manufacturing and operating payments of AUD 1.625 million. These figures show that Investment in commercial operations and product development substantially exceeded early customer cash receipts during the quarter. Receipt timing and recognised accounting revenue should not be treated as interchangeable measures.

Commercialisation Risks and Execution

Artrya (ASX:AYA) faces the execution requirements associated with selling software into complex hospital systems. Contracts need to translate into live installations, clinical usage and recurring billings. The company must also manage product development, regulatory processes, Cybersecurity expectations and cash expenditure. Implementation delays or weaker-than-anticipated scan volumes could affect the timing of customer receipts. None of these factors establishes a cause for the share-price change on 13 November, which is reported independently of the earlier operational announcements.

What to Watch Next

The next measurable indicators include additional SAPPHIRE participant conversions, the number of live US sites, plaque assessment usage and subsequent quarterly cash receipts. Changes in operating expenditure and the progress of the company's product roadmap will also show how commercial expansion is being funded. The November 2026 Annual General Meeting and subsequent company announcements may provide further detail on deployment priorities. The distinction between signed agreements, installations and billable usage remains central when assessing progress.

Key Insights

Artrya has moved beyond product development into initial US commercial deployment, with Huntsville and Tanner providing different indicators of adoption. Its September-quarter statement also demonstrates the gap between early receipts and the cash required for expansion. Future disclosures on customer conversions, platform usage and cash flow will offer clearer evidence of how the commercial model is developing.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.